Signaling by ERBB2 (Homo sapiens)

From WikiPathways

Revision as of 09:25, 11 July 2016 by ReactomeTeam (Talk | contribs)
Jump to: navigation, search
151514540505, 496, 8, 9, 15, 21...513, 14, 3545452, 13, 20, 21, 24...48281148195110285140453, 3512485451169, 271051419, 27, 47117cytosolNeuregulins UBC(229-304) p-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform NRGs/EGFLs:ERBB4:p-Y877-ERBB2 PIK3R1 GRB2-1 UBC(77-152) p-Y349,Y350-SHC1 UBC(457-532) UBC(77-152) ADPRPS27A(1-76) UBC(533-608) UBC(77-152) UBB(1-76) UBC(533-608) ADPRNF41 NRG2 UBC(305-380) MATKp-Y-ERBB2 UbADPNeuregulins UBB(77-152) UBB(1-76) Phosphorylated p-Y877-ERBB2 heterodimers p-Y,Y877-ERBB2 Phosphorylated p-6Y-ERBB2 heterodimers ADPSOS1 NRG1 UBA52(1-76) GRB2-1:SOS1Phosphorylatedp-6Y-ERBB2heterodimersRPS27A(1-76) UBC(1-76) NRG1 RNF41 PIK3R1 UBB(77-152) UBC(457-532) UBB(153-228) p-6Y-ERBB2 UBB(77-152) HSP90AA1 GRB7 UBC(1-76) UBA52(1-76) GRB2:GAB1UBB(153-228) NRG1/2:p-10Y-ERBB3:p-ERBB2:RNF41UBB(153-228) p-7Y-ERBB2 ERBB2IPUBC(1-76) EGF GDPNRG1/2:ERBB3p-10Y-ERBB3-1 ERBB2IP UBC(609-684) UBC(229-304) UBB(77-152) ERBB3-1 PIK3CA NRG2 UBC(533-608) UBA52(1-76) UBB(1-76) UBB(77-152) UBC(229-304) UBB(77-152) UBC(305-380) UBC(609-684) p-10Y-ERBB3-1 NRG2 UbUBC(153-228) ATPp-ERBB2 heterodimersUBC(305-380) p-6Y-EGFR Ub-RNF41UBC(609-684) ERBB3-1 UBC(1-76) UBC(305-380) SOS1 UBC(533-608) EGF RNF41 EGF UBC(609-684) NRG1 PIK3CAGRB2:SOS1:p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersATPUBC(229-304) UBC(457-532) UBC(457-532) CUL5UBC(229-304) UBC(1-76) UBC(305-380) UBC(153-228) UBB(1-76) UBC(609-684) p-Y-ERBB2 EGF EGF UBA52(1-76) UBC(153-228) UBC(609-684) PIK3R1p-6Y-ERBB2 UBC(533-608) Phosphorylated p-6Y-ERBB2 heterodimers ADPp-6Y-ERBB2 EGF:p-EGFR:p-ERBB2:PLCG1UBB(153-228) p-T305,S472-AKT3 PLCG1 UBC(533-608) UBC(381-456) HSP90AA1 p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersUBC(381-456) RPS27A(1-76) HSP90AA1 UBC(153-228) PIP3 activates AKTsignalingUBC(305-380) UBC(305-380) p-6Y-EGFR p21 RAS:GDPRPS27A(1-76) NRG1 CDC37 GRB2-1 ERBB2:ERBB2IP:HSP90:CDC37UBA52(1-76) GRB2-1 ATPUBC(153-228) EGF UBC(153-228) p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform UBC(533-608) ERBB2 UBC(305-380) NRG1 UBB(153-228) UBB(153-228) MATK EGF UBC(77-152) Phosphorylated p-Y877-ERBB2 heterodimers EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PI3KERBB3-1 p-Y349,Y350-SHC1 GAB1 HSP90p-6Y-ERBB2 UBC(381-456) p-7Y-ERBB2 CDC37 UBB(77-152) p-Y,Y877-ERBB2 RNF41 KRAS DAG and IP3signalingp-6Y-ERBB2 UBB(77-152) UBB(1-76) ADPNRG1/2:p-10Y-ERBB3:p-ERBB2:GRB7PIK3R1 Phosphorylated p-6Y-ERBB2 heterodimers NRG1 UBB(77-152) UBB(153-228) p-Y877-ERBB2 ERBB3:RNF41p-10Y-ERBB3-1 UBA52(1-76) UBC(305-380) p-7Y-ERBB2 p-6Y-EGFR ERBB3-1ATPUbp-7Y-ERBB2 SOS1 p-Y419/420/426-N-myristoyl-SRC/FYN/YES1UBC(457-532) NRG1 ADPGRB2-1 p-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform GRB7CDC37 NRG2 GTPPhosphorylated ERBB2:ERBB4cyt2 heterodimers RPS27A(1-76) ERBB2 heterodimersNRG1 UBC(381-456) UBB(77-152) p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform MyrG-p-Y419-SRC Phosphorylated ERBB2:ERBB4cyt1 heterodimers UBC(229-304) p-6Y-EGFR UBC(77-152) PhosphorylatedERBB2:ERBB4heterodimersNRG1/2p-Y-ERBB2 ERBB3-1 PIK3CAp-7Y-ERBB2 p-7Y-ERBB2 PIK3CA EGF-like ligands NRG1/2:Ub-p-10Y-ERBB3:p-ERBB2Neuregulins Phosphorylated p-Y877-ERBB2 heterodimers Phosphorylated ERBB2:ERBB4cyt1 heterodimers UBC(381-456) p-Y-ERBB2 p-Y,Y877-ERBB2 UBC(457-532) p-7Y-ERBB2 ERBB2IP KRAS ERBB2IP EGF-like ligands UBC(533-608) p-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform p-Y877-ERBB2heterodimersADPGAB1 EGF Phosphorylated p-6Y-ERBB2 heterodimers EGF-like ligands UBA52(1-76) ATPNRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PIK3R1UbUBC(609-684) UBC(381-456) UBC(229-304) UBC(381-456) UBC(153-228) UBC(305-380) EGF-like ligands PhosphorylatedERBB2:ERBB3heterodimersNRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PI3Kp-10Y-ERBB3-1 UBA52(1-76) UBC(229-304) UBC(305-380) UBA52(1-76) UbUBC(1-76) p-Y-ERBB2 UBC(77-152) p-6Y-ERBB2 Phosphorylated p-Y877-ERBB2 heterodimers RPS27A(1-76) UBC(1-76) UBC(457-532) UBC(77-152) UBB(1-76) STUB1USP8Phosphorylated p-Y877-ERBB2 heterodimers p-T945-USP8PIK3R1p-7Y-ERBB2 p21 RAS:GTPp-6Y-ERBB2 p-7Y-ERBB2 ERBB2 ERBB4 JM-A CYT-1 isoform UBC(229-304) Ub-ERBB2:ERBB2IP:Ub-HSP90:CDC37GAB1 p-T945-USP8 GAB1 Ub-ERBB3MyrG-p-Y420-FYN UBC(229-304) CDC37UBB(77-152) EGFR ERBB4 JM-A CYT-2 isoform ADPEGFR NRG2 UBC(609-684) UBC(609-684) ERBB3-1 Ub-ERBB2:ERBB2IP:HSP90:CDC37NRG1/2:p-ERBB3:p-ERBB2:PI3KERBB4 JM-B CYT-1 isoform ATPUBC(457-532) UBB(1-76) UBC(381-456) NRG1 UBC(77-152) p-Y-ERBB2 p-Y,Y877-ERBB2 ERBB2 NRG2 RPS27A(1-76) p-T308,S473-AKT1 UBB(77-152) ERBB3-1 ATPEGF:p-EGFR:p-ERBB2:GRB2:GAB1:PIK3R1p-Y,Y877-ERBB2 UBC(457-532) p-6Y-EGFR UBA52(1-76) PI(3,4,5)P3p-6Y-EGFR PhosphorylatedERBB2:ERBB4cyt1heterodimersSHC1RAF/MAP kinasecascadeUBC(77-152) UBB(1-76) Ub-RNF41:p-USP8NRGs/EGFLs:ERBB4:ERBB2 UBB(153-228) RPS27A(1-76) UBA52(1-76) UBB(153-228) NRG1 p-10Y-ERBB3-1 UBC(305-380) p-6Y-EGFR p-ERBB2heterodimers:MATKPIK3R1 PI(4,5)P2UBB(1-76) SHC1 NRG2 UBB(153-228) NRG2 RPS27A(1-76) SOS1 NRG2 UbNRGs/EGFLs:p-ERBB4:p-7Y-ERBB2 HRAS UBC(609-684) HRAS UBB(1-76) UBC(381-456) p-6Y-EGFR UBC(533-608) p-6Y-ERBB2 NRGs/EGFLs:p-ERBB4:p-6Y-ERBB2 MyrG-p-Y426-YES1 SHC1:PhosphorylatedERBB2 heterodimersUBC(153-228) p-Y,Y877-ERBB2 CDC37 NRG2 p-T309,S474-AKT2 Neuregulins UBB(1-76) RPS27A(1-76) GRB2-1 NRG1 UBC(533-608) UBC(381-456) UBC(77-152) NRG1 UBC(533-608) RNF41UBC(381-456) UBC(153-228) RPS27A(1-76) UBC(457-532) GRB2-1 p-7Y-ERBB2 UBC(533-608) NRGs/EGFLs:p-ERBB4:p-ERBB2:GRB2:SOS1Phosphorylated p-6Y-ERBB2 heterodimers UBC(609-684) p-4Y-PLCG1PLCG1UBB(1-76) GRB2-1 UBC(229-304) NRAS Phosphorylated ERBB2:ERBB4cyt2 heterodimers GRB2-1 UBC(457-532) EGF:p-EGFR:p-ERBB2:GRB2:GAB1p-6Y-ERBB2 Ligand-ActivatedEGFR/ERBB3/ERBB4p-10Y-ERBB3-1 PIK3R1 UBB(153-228) p-10Y-ERBB3-1 UBC(229-304) PIK3CA NRG2 NRG2 UBC(77-152) p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform UBC(1-76) GTP EGFR UBC(609-684) EGF Active AKTATPUBC(457-532) EGF UBC(1-76) RPS27A(1-76) UBC(1-76) UBB(153-228) GDP EGF NRG1 p-Y-ERBB2 UBC(153-228) HSP90AA1 p-Y,Y877-ERBB2 ERBB2 NRG2 UBA52(1-76) PIK3R1 ATPp-10Y-ERBB3-1 NRG1/2:p-ERBB3:p-ERBB2:PIK3R1p-6Y-ERBB2 EGF:p-EGFR:p-ERBB2:GRB2:SOS1UBC(153-228) Phosphorylatedp-Y877-ERBB2heterodimersUBC(381-456) PhosphorylatedERBB2:EGFRheterodimersUBC(153-228) UBC(1-76) NRAS UBC(1-76) UBC(77-152) 4718, 22, 25, 26, 30...


Description

ERBB2, also known as HER2 or NEU, is a receptor tyrosine kinase (RTK) belonging to the EGFR family. ERBB2 possesses an extracellular domain that does not bind any known ligand, contrary to other EGFR family members, a single transmembrane domain, and an intracellular domain consisting of an active kinase and a C-tail with multiple tyrosine phosphorylation sites. Inactive ERBB2 is associated with a chaperone heat shock protein 90 (HSP90) and its co-chaperone CDC37 (Xu et al. 2001, Citri et al. 2004, Xu et al. 2005). In addition, ERBB2 is associated with ERBB2IP (also known as ERBIN or LAP2), a protein responsible for proper localization of ERBB2. In epithelial cells, ERBB2IP restricts expression of ERBB2 to basolateral plasma membrane regions (Borg et al. 2000).

ERBB2 becomes activated by forming a heterodimer with another ligand-activated EGFR family member, either EGFR, ERBB3 or ERBB4, which is accompanied by dissociation of chaperoning proteins HSP90 and CDC37 (Citri et al. 2004), as well as ERBB2IP (Borg et al. 2000) from ERBB2. ERBB2 heterodimers function to promote cell proliferation, cell survival and differentiation, depending on the cellular context. ERBB2 can also be activated by homodimerization when it is overexpressed, in cancer for example.

In cells expressing both ERBB2 and EGFR, EGF stimulation of EGFR leads to formation of both ERBB2:EGFR heterodimers (Wada et al. 1990, Karunagaran et al. 1996) and EGFR homodimers. Heterodimers of ERBB2 and EGFR trans-autophosphorylate on twelve tyrosine residues, six in the C-tail of EGFR and six in the C-tail of ERBB2 - Y1023, Y1139, Y1196, Y1221, Y1222 and Y1248 (Margolis et al. 1989, Hazan et al. 1990,Walton et al. 1990, Helin et al. 1991, Ricci et al. 1995, Pinkas-Kramarski 1996). Phosphorylated tyrosine residues in the C-tail of EGFR and ERBB2 serve as docking sites for downstream signaling molecules. Three key signaling pathways activated by ERBB2:EGFR heterodimers are RAF/MAP kinase cascade, PI3K-induced AKT signaling, and signaling by phospholipase C gamma (PLCG1). Downregulation of EGFR signaling is mediated by ubiquitin ligase CBL, and is shown under Signaling by EGFR.

In cells expressing ERBB2 and ERBB3, ERBB3 activated by neuregulin NRG1 or NRG2 binding (Tzahar et al. 1994) forms a heterodimer with ERBB2 (Pinkas-Kramarski et al. 1996, Citri et al. 2004). ERBB3 is the only EGFR family member with no kinase activity, and can only function in heterodimers, with ERBB2 being its preferred heterodimerization partner. After heterodimerization, ERBB2 phosphorylates ten tyrosine residues in the C-tail of ERBB3, Y1054, Y1197, Y1199, Y1222, Y1224, Y1260, Y1262, Y1276, Y1289 and Y1328 (Prigent et al. 1994, Pinkas-Kramarski et al. 1996, Vijapurkar et al. 2003, Li et al. 2007) that subsequently serve as docking sites for downstream signaling molecules, resulting in activation of PI3K-induced AKT signaling and RAF/MAP kinase cascade. Signaling by ERBB3 is downregulated by the action of RNF41 ubiquitin ligase, also known as NRDP1.

In cells expressing ERBB2 and ERBB4, ligand stimulated ERBB4 can either homodimerize or form heterodimers with ERBB2 (Li et al. 2007), resulting in trans-autophosphorylation of ERBB2 and ERBB4 on C-tail tyrosine residues that will subsequently serve as docking sites for downstream signaling molecules, leading to activation of RAF/MAP kinase cascade and, in the case of ERBB4 CYT1 isoforms, PI3K-induced AKT signaling (Hazan et al. 1990, Cohen et al. 1996, Li et al. 2007, Kaushansky et al. 2008). Signaling by ERBB4 is downregulated by the action of WWP1 and ITCH ubiquitin ligases, and is shown under Signaling by ERBB4.

View original pathway at:Reactome.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Faisal A, el-Shemerly M, Hess D, Nagamine Y.; ''Serine/threonine phosphorylation of ShcA. Regulation of protein-tyrosine phosphatase-pest binding and involvement in insulin signaling.''; PubMed Europe PMC Scholia
  2. Lammers M, Rose R, Scrima A, Wittinghofer A.; ''The regulation of mDia1 by autoinhibition and its release by Rho*GTP.''; PubMed Europe PMC Scholia
  3. Fan G, Lin G, Lucito R, Tonks NK.; ''Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells.''; PubMed Europe PMC Scholia
  4. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF.; ''Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.''; PubMed Europe PMC Scholia
  5. Keranen LM, Dutil EM, Newton AC.; ''Protein kinase C is regulated in vivo by three functionally distinct phosphorylations.''; PubMed Europe PMC Scholia
  6. Yasuda S, Oceguera-Yanez F, Kato T, Okamoto M, Yonemura S, Terada Y, Ishizaki T, Narumiya S.; ''Cdc42 and mDia3 regulate microtubule attachment to kinetochores.''; PubMed Europe PMC Scholia
  7. Derry JJ, Richard S, Valderrama Carvajal H, Ye X, Vasioukhin V, Cochrane AW, Chen T, Tyner AL.; ''Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability.''; PubMed Europe PMC Scholia
  8. Romero S, Le Clainche C, Didry D, Egile C, Pantaloni D, Carlier MF.; ''Formin is a processive motor that requires profilin to accelerate actin assembly and associated ATP hydrolysis.''; PubMed Europe PMC Scholia
  9. Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T, Pelicci PG.; ''Shc products are substrates of erbB-2 kinase.''; PubMed Europe PMC Scholia
  10. Chakraborty G, Jain S, Kundu GC.; ''Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.''; PubMed Europe PMC Scholia
  11. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K.; ''The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells.''; PubMed Europe PMC Scholia
  12. Songyang Z, Margolis B, Chaudhuri M, Shoelson SE, Cantley LC.; ''The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif.''; PubMed Europe PMC Scholia
  13. Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA.; ''Regulated association of protein kinase B/Akt with breast tumor kinase.''; PubMed Europe PMC Scholia
  14. Haegebarth A, Heap D, Bie W, Derry JJ, Richard S, Tyner AL.; ''The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2.''; PubMed Europe PMC Scholia
  15. Kang SA, Lee ST.; ''PTK6 promotes degradation of c-Cbl through PTK6-mediated phosphorylation.''; PubMed Europe PMC Scholia
  16. Bione S, Sala C, Manzini C, Arrigo G, Zuffardi O, Banfi S, Borsani G, Jonveaux P, Philippe C, Zuccotti M, Ballabio A, Toniolo D.; ''A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility.''; PubMed Europe PMC Scholia
  17. Janes PW, Daly RJ, deFazio A, Sutherland RL.; ''Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.''; PubMed Europe PMC Scholia
  18. Zheng Y, Asara JM, Tyner AL.; ''Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRK-associated substrate.''; PubMed Europe PMC Scholia
  19. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS.; ''Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling.''; PubMed Europe PMC Scholia
  20. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ, Page MJ, Gusterson BA, Crompton MR.; ''Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor.''; PubMed Europe PMC Scholia
  21. Wada T, Qian XL, Greene MI.; ''Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.''; PubMed Europe PMC Scholia
  22. Vijapurkar U, Kim MS, Koland JG.; ''Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.''; PubMed Europe PMC Scholia
  23. Yayoshi-Yamamoto S, Taniuchi I, Watanabe T.; ''FRL, a novel formin-related protein, binds to Rac and regulates cell motility and survival of macrophages.''; PubMed Europe PMC Scholia
  24. Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW, Prodromou C, Pearl LH.; ''The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37).''; PubMed Europe PMC Scholia
  25. Pires IM, Blokland NJ, Broos AW, Poujade FA, Senra JM, Eccles SA, Span PN, Harvey AJ, Hammond EM.; ''HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.''; PubMed Europe PMC Scholia
  26. Hazan R, Margolis B, Dombalagian M, Ullrich A, Zilberstein A, Schlessinger J.; ''Identification of autophosphorylation sites of HER2/neu.''; PubMed Europe PMC Scholia
  27. Ikeda O, Sekine Y, Mizushima A, Nakasuji M, Miyasaka Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T.; ''Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.''; PubMed Europe PMC Scholia
  28. Colón-Franco JM, Gomez TS, Billadeau DD.; ''Dynamic remodeling of the actin cytoskeleton by FMNL1γ is required for structural maintenance of the Golgi complex.''; PubMed Europe PMC Scholia
  29. Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A.; ''Memo mediates ErbB2-driven cell motility.''; PubMed Europe PMC Scholia
  30. Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A, Taylor L, Tate SA, Hardy WR, Colwill K, Dai AY, Bagshaw R, Dennis JW, Gingras AC, Daly RJ, Pawson T.; ''Temporal regulation of EGF signalling networks by the scaffold protein Shc1.''; PubMed Europe PMC Scholia
  31. Prigent SA, Gullick WJ.; ''Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera.''; PubMed Europe PMC Scholia
  32. Kaushansky A, Gordus A, Budnik BA, Lane WS, Rush J, MacBeath G.; ''System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.''; PubMed Europe PMC Scholia
  33. Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, Yu M, Miller WT, Muthuswamy SK.; ''Brk is coamplified with ErbB2 to promote proliferation in breast cancer.''; PubMed Europe PMC Scholia
  34. Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L.; ''Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.''; PubMed Europe PMC Scholia
  35. Habib T, Herrera R, Decker SJ.; ''Activators of protein kinase C stimulate association of Shc and the PEST tyrosine phosphatase.''; PubMed Europe PMC Scholia
  36. Feracci M, Pimentel C, Bornet O, Roche P, Salaun D, Badache A, Guerlesquin F.; ''MEMO associated with an ErbB2 receptor phosphopeptide reveals a new phosphotyrosine motif.''; PubMed Europe PMC Scholia
  37. Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A, Schlessinger J.; ''All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor.''; PubMed Europe PMC Scholia
  38. Tanizaki J, Okamoto I, Sakai K, Nakagawa K.; ''Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.''; PubMed Europe PMC Scholia
  39. Kyriakis JM, Avruch J.; ''Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update.''; PubMed Europe PMC Scholia
  40. Soler C, Alvarez CV, Beguinot L, Carpenter G.; ''Potent SHC tyrosine phosphorylation by epidermal growth factor at low receptor density or in the absence of receptor autophosphorylation sites.''; PubMed Europe PMC Scholia
  41. Shen CH, Chen HY, Lin MS, Li FY, Chang CC, Kuo ML, Settleman J, Chen RH.; ''Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.''; PubMed Europe PMC Scholia
  42. Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C, Daly RJ.; ''Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3.''; PubMed Europe PMC Scholia
  43. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Adélaïde J, Margolis B, Birnbaum D.; ''ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor.''; PubMed Europe PMC Scholia
  44. Davidson D, Veillette A.; ''PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates.''; PubMed Europe PMC Scholia
  45. Roskoski R.; ''ERK1/2 MAP kinases: structure, function, and regulation.''; PubMed Europe PMC Scholia
  46. Lukong KE, Richard S.; ''Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration.''; PubMed Europe PMC Scholia
  47. Otomo T, Otomo C, Tomchick DR, Machius M, Rosen MK.; ''Structural basis of Rho GTPase-mediated activation of the formin mDia1.''; PubMed Europe PMC Scholia
  48. Gao Y, Cimica V, Reich NC.; ''Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.''; PubMed Europe PMC Scholia
  49. Gasman S, Kalaidzidis Y, Zerial M.; ''RhoD regulates endosome dynamics through Diaphanous-related Formin and Src tyrosine kinase.''; PubMed Europe PMC Scholia
  50. Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA.; ''Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.''; PubMed Europe PMC Scholia
  51. Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D.; ''ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.''; PubMed Europe PMC Scholia
  52. Wallar BJ, Deward AD, Resau JH, Alberts AS.; ''RhoB and the mammalian Diaphanous-related formin mDia2 in endosome trafficking.''; PubMed Europe PMC Scholia
  53. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L.; ''Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.''; PubMed Europe PMC Scholia
  54. Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R.; ''Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC.''; PubMed Europe PMC Scholia
  55. McKay MM, Morrison DK.; ''Integrating signals from RTKs to ERK/MAPK.''; PubMed Europe PMC Scholia
  56. Zaoui K, Benseddik K, Daou P, Salaün D, Badache A.; ''ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells.''; PubMed Europe PMC Scholia
  57. Xu W, Yuan X, Beebe K, Xiang Z, Neckers L.; ''Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.''; PubMed Europe PMC Scholia
  58. Helin K, Beguinot L.; ''Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines.''; PubMed Europe PMC Scholia
  59. Miralles F, Posern G, Zaromytidou AI, Treisman R.; ''Actin dynamics control SRF activity by regulation of its coactivator MAL.''; PubMed Europe PMC Scholia
  60. Fernandez-Borja M, Janssen L, Verwoerd D, Hordijk P, Neefjes J.; ''RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1.''; PubMed Europe PMC Scholia
  61. Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K.; ''A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.''; PubMed Europe PMC Scholia
  62. Yang S, Raymond-Stintz MA, Ying W, Zhang J, Lidke DS, Steinberg SL, Williams L, Oliver JM, Wilson BS.; ''Mapping ErbB receptors on breast cancer cell membranes during signal transduction.''; PubMed Europe PMC Scholia
  63. Patel P, Asbach B, Shteyn E, Gomez C, Coltoff A, Bhuyan S, Tyner AL, Wagner R, Blain SW.; ''Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4.''; PubMed Europe PMC Scholia
  64. Cseh B, Doma E, Baccarini M.; ''"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.''; PubMed Europe PMC Scholia
  65. Li F, Higgs HN.; ''The mouse Formin mDia1 is a potent actin nucleation factor regulated by autoinhibition.''; PubMed Europe PMC Scholia
  66. Li Z, Mei Y, Liu X, Zhou M.; ''Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.''; PubMed Europe PMC Scholia
  67. Kovar DR, Harris ES, Mahaffy R, Higgs HN, Pollard TD.; ''Control of the assembly of ATP- and ADP-actin by formins and profilin.''; PubMed Europe PMC Scholia
  68. Medzihradszky KF, Phillipps NJ, Senderowicz L, Wang P, Turck CW.; ''Synthesis and characterization of histidine-phosphorylated peptides.''; PubMed Europe PMC Scholia
  69. Chattopadhyay A, Vecchi M, Ji Q, Mernaugh R, Carpenter G.; ''The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor.''; PubMed Europe PMC Scholia
  70. Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T.; ''Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.''; PubMed Europe PMC Scholia
  71. Dutil EM, Toker A, Newton AC.; ''Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1).''; PubMed Europe PMC Scholia
  72. Ono H, Basson MD, Ito H.; ''PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling.''; PubMed Europe PMC Scholia
  73. Walton GM, Chen WS, Rosenfeld MG, Gill GN.; ''Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates.''; PubMed Europe PMC Scholia
  74. Zheng Y, Peng M, Wang Z, Asara JM, Tyner AL.; ''Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor.''; PubMed Europe PMC Scholia
  75. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z.; ''Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.''; PubMed Europe PMC Scholia
  76. Cao Z, Wu X, Yen L, Sweeney C, Carraway KL.; ''Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.''; PubMed Europe PMC Scholia
  77. Gao GX, Dong HJ, Gu HT, Gao Y, Pan YZ, Yang Y, Chen XQ.; ''[PI3-kinase mediates activity of RhoA and interaction of RhoA with mDia1 in thrombin-induced platelet aggregation].''; PubMed Europe PMC Scholia
  78. Qiu XB, Goldberg AL.; ''Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3.''; PubMed Europe PMC Scholia
  79. Lukong KE, Larocque D, Tyner AL, Richard S.; ''Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression.''; PubMed Europe PMC Scholia
  80. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y.; ''ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.''; PubMed Europe PMC Scholia
  81. Lukong KE, Huot ME, Richard S.; ''BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest.''; PubMed Europe PMC Scholia
  82. Fan G, Aleem S, Yang M, Miller WT, Tonks NK.; ''Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.''; PubMed Europe PMC Scholia
  83. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA.; ''Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.''; PubMed Europe PMC Scholia
  84. Seth A, Otomo C, Rosen MK.; ''Autoinhibition regulates cellular localization and actin assembly activity of the diaphanous-related formins FRLalpha and mDia1.''; PubMed Europe PMC Scholia
  85. Cargnello M, Roux PP.; ''Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.''; PubMed Europe PMC Scholia
  86. Peng M, Ball-Kell SM, Tyner AL.; ''Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.''; PubMed Europe PMC Scholia
  87. Habas R, Kato Y, He X.; ''Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1.''; PubMed Europe PMC Scholia
  88. Sepp-Lorenzino L, Eberhard I, Ma Z, Cho C, Serve H, Liu F, Rosen N, Lupu R.; ''Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.''; PubMed Europe PMC Scholia
  89. Patterson RL, van Rossum DB, Nikolaidis N, Gill DL, Snyder SH.; ''Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling.''; PubMed Europe PMC Scholia
  90. Zaoui K, Honoré S, Isnardon D, Braguer D, Badache A.; ''Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells.''; PubMed Europe PMC Scholia
  91. Li D, Sewer MB.; ''RhoA and DIAPH1 mediate adrenocorticotropin-stimulated cortisol biosynthesis by regulating mitochondrial trafficking.''; PubMed Europe PMC Scholia
  92. Kang SA, Lee ES, Yoon HY, Randazzo PA, Lee ST.; ''PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.''; PubMed Europe PMC Scholia
  93. Nezami AG, Poy F, Eck MJ.; ''Structure of the autoinhibitory switch in formin mDia1.''; PubMed Europe PMC Scholia
  94. Ricci A, Lanfrancone L, Chiari R, Belardo G, Pertica C, Natali PG, Pelicci PG, Segatto O.; ''Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase.''; PubMed Europe PMC Scholia
  95. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y.; ''Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.''; PubMed Europe PMC Scholia
  96. Cantwell-Dorris ER, O'Leary JJ, Sheils OM.; ''BRAFV600E: implications for carcinogenesis and molecular therapy.''; PubMed Europe PMC Scholia
  97. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH.; ''Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.''; PubMed Europe PMC Scholia
  98. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG.; ''Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.''; PubMed Europe PMC Scholia
  99. Ehrlich ES, Wang T, Luo K, Xiao Z, Niewiadomska AM, Martinez T, Xu W, Neckers L, Yu XF.; ''Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase.''; PubMed Europe PMC Scholia
  100. Roberts PJ, Der CJ.; ''Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.''; PubMed Europe PMC Scholia
  101. Wellbrock C, Karasarides M, Marais R.; ''The RAF proteins take centre stage.''; PubMed Europe PMC Scholia
  102. Roskoski R.; ''MEK1/2 dual-specificity protein kinases: structure and regulation.''; PubMed Europe PMC Scholia
  103. Cohen BD, Green JM, Foy L, Fell HP.; ''HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers.''; PubMed Europe PMC Scholia
  104. Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, Bar-Sagi D.; ''Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.''; PubMed Europe PMC Scholia
  105. Roskoski R.; ''RAF protein-serine/threonine kinases: structure and regulation.''; PubMed Europe PMC Scholia
  106. Goel RK, Lukong KE.; ''Tracing the footprints of the breast cancer oncogene BRK - Past till present.''; PubMed Europe PMC Scholia
  107. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.; ''Mutations of the BRAF gene in human cancer.''; PubMed Europe PMC Scholia
  108. Wang HM, Xu YF, Ning SL, Yang DX, Li Y, Du YJ, Yang F, Zhang Y, Liang N, Yao W, Zhang LL, Gu LC, Gao CJ, Pang Q, Chen YX, Xiao KH, Ma R, Yu X, Sun JP.; ''The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes.''; PubMed Europe PMC Scholia
  109. Brown MD, Sacks DB.; ''Protein scaffolds in MAP kinase signalling.''; PubMed Europe PMC Scholia
  110. Plotnikov A, Zehorai E, Procaccia S, Seger R.; ''The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation.''; PubMed Europe PMC Scholia
  111. Vega FM, Fruhwirth G, Ng T, Ridley AJ.; ''RhoA and RhoC have distinct roles in migration and invasion by acting through different targets.''; PubMed Europe PMC Scholia
  112. Kühn S, Geyer M.; ''Formins as effector proteins of Rho GTPases.''; PubMed Europe PMC Scholia
  113. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A.; ''Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.''; PubMed Europe PMC Scholia
  114. Xu Y, Moseley JB, Sagot I, Poy F, Pellman D, Goode BL, Eck MJ.; ''Crystal structures of a Formin Homology-2 domain reveal a tethered dimer architecture.''; PubMed Europe PMC Scholia
  115. Gensler M, Buschbeck M, Ullrich A.; ''Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1.''; PubMed Europe PMC Scholia
  116. Cheng L, Zhang J, Ahmad S, Rozier L, Yu H, Deng H, Mao Y.; ''Aurora B regulates formin mDia3 in achieving metaphase chromosome alignment.''; PubMed Europe PMC Scholia
  117. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX.; ''Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.''; PubMed Europe PMC Scholia
  118. Fukumoto T, Kubota Y, Kitanaka A, Yamaoka G, Ohara-Waki F, Imataki O, Ohnishi H, Ishida T, Tanaka T.; ''Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.''; PubMed Europe PMC Scholia
  119. Xie Y, Pendergast AM, Hung MC.; ''Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu.''; PubMed Europe PMC Scholia
  120. Batzer AG, Blaikie P, Nelson K, Schlessinger J, Margolis B.; ''The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor.''; PubMed Europe PMC Scholia
  121. Qiu C, Lienhard S, Hynes NE, Badache A, Leahy DJ.; ''Memo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active site.''; PubMed Europe PMC Scholia
  122. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y.; ''Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.''; PubMed Europe PMC Scholia
  123. Turjanski AG, Vaqué JP, Gutkind JS.; ''MAP kinases and the control of nuclear events.''; PubMed Europe PMC Scholia
  124. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L.; ''Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.''; PubMed Europe PMC Scholia
  125. Castro NE, Lange CA.; ''Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.''; PubMed Europe PMC Scholia
  126. Fazioli F, Kim UH, Rhee SG, Molloy CJ, Segatto O, Di Fiore PP.; ''The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency.''; PubMed Europe PMC Scholia
  127. Fan L, Pellegrin S, Scott A, Mellor H.; ''The small GTPase Rif is an alternative trigger for the formation of actin stress fibers in epithelial cells.''; PubMed Europe PMC Scholia
  128. Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A, Yoshimura A, Matsuda T.; ''STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.''; PubMed Europe PMC Scholia
  129. Zrihan-Licht S, Deng B, Yarden Y, McShan G, Keydar I, Avraham H.; ''Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation.''; PubMed Europe PMC Scholia
  130. Kamalati T, Jolin HE, Fry MJ, Crompton MR.; ''Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation.''; PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
101567view11:43, 1 November 2018ReactomeTeamreactome version 66
101103view21:27, 31 October 2018ReactomeTeamreactome version 65
100632view20:01, 31 October 2018ReactomeTeamreactome version 64
100182view16:46, 31 October 2018ReactomeTeamreactome version 63
99732view15:12, 31 October 2018ReactomeTeamreactome version 62 (2nd attempt)
94020view13:52, 16 August 2017ReactomeTeamreactome version 61
93639view11:29, 9 August 2017ReactomeTeamreactome version 61
87120view18:38, 18 July 2016EgonwOntology Term : 'signaling pathway' added !
86754view09:25, 11 July 2016ReactomeTeamreactome version 56
83403view11:08, 18 November 2015ReactomeTeamVersion54
81604view13:08, 21 August 2015ReactomeTeamVersion53
77062view08:36, 17 July 2014ReactomeTeamFixed remaining interactions
76767view12:13, 16 July 2014ReactomeTeamFixed remaining interactions
76090view10:15, 11 June 2014ReactomeTeamRe-fixing comment source
75801view11:33, 10 June 2014ReactomeTeamReactome 48 Update
75152view14:10, 8 May 2014AnweshaFixing comment source for displaying WikiPathways description
74799view08:53, 30 April 2014ReactomeTeamNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
ADPMetaboliteCHEBI:16761 (ChEBI)
ATPMetaboliteCHEBI:15422 (ChEBI)
Active AKTComplexR-HSA-202074 (Reactome)
CDC37 ProteinQ16543 (Uniprot-TrEMBL)
CDC37ComplexR-HSA-1225828 (Reactome)
CUL5ProteinQ93034 (Uniprot-TrEMBL)
DAG and IP3 signalingPathwayR-HSA-1489509 (Reactome) This pathway describes the generation of DAG and IP3 by the PLCgamma-mediated hydrolysis of PIP2 and the subsequent downstream signaling events.
EGF ProteinP01133 (Uniprot-TrEMBL)
EGF-like ligands R-HSA-1233230 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PI3KComplexR-HSA-1306961 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PIK3R1ComplexR-HSA-1306962 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1ComplexR-HSA-1306958 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:SOS1ComplexR-HSA-1250505 (Reactome)
EGF:p-EGFR:p-ERBB2:PLCG1ComplexR-HSA-1251942 (Reactome)
EGFR ProteinP00533 (Uniprot-TrEMBL)
ERBB2 ProteinP04626 (Uniprot-TrEMBL)
ERBB2 heterodimersComplexR-HSA-1963573 (Reactome)
ERBB2:ERBB2IP:HSP90:CDC37ComplexR-HSA-1227970 (Reactome)
ERBB2IP ProteinQ96RT1 (Uniprot-TrEMBL)
ERBB2IPProteinQ96RT1 (Uniprot-TrEMBL)
ERBB3-1 ProteinP21860-1 (Uniprot-TrEMBL)
ERBB3-1ProteinP21860-1 (Uniprot-TrEMBL)
ERBB3:RNF41ComplexR-HSA-1358732 (Reactome)
ERBB4 JM-A CYT-1 isoform ProteinQ15303-1 (Uniprot-TrEMBL)
ERBB4 JM-A CYT-2 isoform ProteinQ15303-3 (Uniprot-TrEMBL)
ERBB4 JM-B CYT-1 isoform ProteinQ15303-2 (Uniprot-TrEMBL)
GAB1 ProteinQ13480 (Uniprot-TrEMBL)
GDP MetaboliteCHEBI:17552 (ChEBI)
GDPMetaboliteCHEBI:17552 (ChEBI)
GRB2-1 ProteinP62993-1 (Uniprot-TrEMBL)
GRB2-1:SOS1ComplexR-HSA-109797 (Reactome)
GRB2:GAB1ComplexR-HSA-179849 (Reactome)
GRB2:SOS1:p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersComplexR-HSA-1250479 (Reactome)
GRB7 ProteinQ14451 (Uniprot-TrEMBL)
GRB7ProteinQ14451 (Uniprot-TrEMBL)
GTP MetaboliteCHEBI:15996 (ChEBI)
GTPMetaboliteCHEBI:15996 (ChEBI)
HRAS ProteinP01112 (Uniprot-TrEMBL)
HSP90AA1 ProteinP07900 (Uniprot-TrEMBL)
HSP90ComplexR-HSA-1221657 (Reactome)
KRAS ProteinP01116 (Uniprot-TrEMBL)
Ligand-Activated EGFR/ERBB3/ERBB4ComplexR-HSA-1963571 (Reactome)
MATK ProteinP42679 (Uniprot-TrEMBL)
MATKProteinP42679 (Uniprot-TrEMBL)
MyrG-p-Y419-SRC ProteinP12931 (Uniprot-TrEMBL)
MyrG-p-Y420-FYN ProteinP06241 (Uniprot-TrEMBL)
MyrG-p-Y426-YES1 ProteinP07947 (Uniprot-TrEMBL)
NRAS ProteinP01111 (Uniprot-TrEMBL)
NRG1 R-HSA-1233225 (Reactome)
NRG1/2:ERBB3ComplexR-HSA-1247495 (Reactome)
NRG1/2:Ub-p-10Y-ERBB3:p-ERBB2ComplexR-HSA-1358729 (Reactome)
NRG1/2:p-10Y-ERBB3:p-ERBB2:GRB7ComplexR-HSA-1306951 (Reactome)
NRG1/2:p-10Y-ERBB3:p-ERBB2:RNF41ComplexR-HSA-1358734 (Reactome)
NRG1/2:p-ERBB3:p-ERBB2:PI3KComplexR-HSA-1250508 (Reactome)
NRG1/2:p-ERBB3:p-ERBB2:PIK3R1ComplexR-HSA-1250191 (Reactome)
NRG1/2ComplexR-HSA-1227956 (Reactome)
NRG2 ProteinO14511 (Uniprot-TrEMBL)
NRGs/EGFLs:ERBB4:ERBB2 R-HSA-1250224 (Reactome)
NRGs/EGFLs:ERBB4:p-Y877-ERBB2 R-HSA-1810435 (Reactome)
NRGs/EGFLs:p-ERBB4:p-6Y-ERBB2 R-HSA-1963594 (Reactome)
NRGs/EGFLs:p-ERBB4:p-7Y-ERBB2 R-HSA-1368190 (Reactome)
NRGs/EGFLs:p-ERBB4:p-ERBB2:GRB2:SOS1ComplexR-HSA-1306947 (Reactome)
NRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PI3KComplexR-HSA-1306974 (Reactome)
NRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PIK3R1ComplexR-HSA-1306942 (Reactome)
Neuregulins R-HSA-1227957 (Reactome)
PI(3,4,5)P3MetaboliteCHEBI:16618 (ChEBI)
PI(4,5)P2MetaboliteCHEBI:18348 (ChEBI)
PIK3CA ProteinP42336 (Uniprot-TrEMBL)
PIK3CAProteinP42336 (Uniprot-TrEMBL)
PIK3R1 ProteinP27986 (Uniprot-TrEMBL)
PIK3R1ProteinP27986 (Uniprot-TrEMBL)
PIP3 activates AKT signalingPathwayR-HSA-1257604 (Reactome) Signaling by AKT is one of the key outcomes of receptor tyrosine kinase (RTK) activation. AKT is activated by the cellular second messenger PIP3, a phospholipid that is generated by PI3K. In ustimulated cells, PI3K class IA enzymes reside in the cytosol as inactive heterodimers composed of p85 regulatory subunit and p110 catalytic subunit. In this complex, p85 stabilizes p110 while inhibiting its catalytic activity. Upon binding of extracellular ligands to RTKs, receptors dimerize and undergo autophosphorylation. The regulatory subunit of PI3K, p85, is recruited to phosphorylated cytosolic RTK domains either directly or indirectly, through adaptor proteins, leading to a conformational change in the PI3K IA heterodimer that relieves inhibition of the p110 catalytic subunit. Activated PI3K IA phosphorylates PIP2, converting it to PIP3; this reaction is negatively regulated by PTEN phosphatase. PIP3 recruits AKT to the plasma membrane, allowing TORC2 to phosphorylate a conserved serine residue of AKT. Phosphorylation of this serine induces a conformation change in AKT, exposing a conserved threonine residue that is then phosphorylated by PDPK1 (PDK1). Phosphorylation of both the threonine and the serine residue is required to fully activate AKT. The active AKT then dissociates from PIP3 and phosphorylates a number of cytosolic and nuclear proteins that play important roles in cell survival and metabolism. For a recent review of AKT signaling, please refer to Manning and Cantley, 2007.
PLCG1 ProteinP19174 (Uniprot-TrEMBL)
PLCG1ProteinP19174 (Uniprot-TrEMBL)
Phosphorylated

ERBB2:EGFR

heterodimers		ComplexR-HSA-1963587 (Reactome)
Phosphorylated

ERBB2:ERBB3

heterodimers		ComplexR-HSA-1963572 (Reactome)
Phosphorylated

ERBB2:ERBB4

heterodimers		ComplexR-HSA-1963592 (Reactome)
Phosphorylated

ERBB2:ERBB4cyt1

heterodimers		ComplexR-HSA-1963568 (Reactome)
Phosphorylated

p-6Y-ERBB2

heterodimers		ComplexR-HSA-1963585 (Reactome)
Phosphorylated

p-Y877-ERBB2

heterodimers		ComplexR-HSA-1963580 (Reactome)
Phosphorylated ERBB2:ERBB4cyt1 heterodimers R-HSA-1963568 (Reactome)
Phosphorylated ERBB2:ERBB4cyt2 heterodimers R-HSA-1963591 (Reactome)
Phosphorylated p-6Y-ERBB2 heterodimers R-HSA-1963585 (Reactome)
Phosphorylated p-Y877-ERBB2 heterodimers R-HSA-1963580 (Reactome)
RAF/MAP kinase cascadePathwayR-HSA-5673001 (Reactome) The RAS-RAF-MEK-ERK pathway regulates processes such as proliferation, differentiation, survival, senescence and cell motility in response to growth factors, hormones and cytokines, among others. Binding of these stimuli to receptors in the plasma membrane promotes the GEF-mediated activation of RAS at the plasma membrane and initiates the three-tiered kinase cascade of the conventional MAPK cascades. GTP-bound RAS recruits RAF (the MAPK kinase kinase), and promotes its dimerization and activation (reviewed in Cseh et al, 2014; Roskoski, 2010; McKay and Morrison, 2007; Wellbrock et al, 2004). Activated RAF phosphorylates the MAPK kinase proteins MEK1 and MEK2 (also known as MAP2K1 and MAP2K2), which in turn phophorylate the proline-directed kinases ERK1 and 2 (also known as MAPK3 and MAPK1) (reviewed in Roskoski, 2012a, b; Kryiakis and Avruch, 2012). Activated ERK proteins may undergo dimerization and have identified targets in both the nucleus and the cytosol; consistent with this, a proportion of activated ERK protein relocalizes to the nucleus in response to stimuli (reviewed in Roskoski 2012b; Turjanski et al, 2007; Plotnikov et al, 2010; Cargnello et al, 2011). Although initially seen as a linear cascade originating at the plasma membrane and culminating in the nucleus, the RAS/RAF MAPK cascade is now also known to be activated from various intracellular location. Temporal and spatial specificity of the cascade is achieved in part through the interaction of pathway components with numerous scaffolding proteins (reviewed in McKay and Morrison, 2007; Brown and Sacks, 2009).
The importance of the RAS/RAF MAPK cascade is highlighted by the fact that components of this pathway are mutated with high frequency in a large number of human cancers. Activating mutations in RAS are found in approximately one third of human cancers, while ~8% of tumors express an activated form of BRAF (Roberts and Der, 2007; Davies et al, 2002; Cantwell-Dorris et al, 2011).
RNF41 ProteinQ9H4P4 (Uniprot-TrEMBL)
RNF41ProteinQ9H4P4 (Uniprot-TrEMBL)
RPS27A(1-76) ProteinP62979 (Uniprot-TrEMBL)
SHC1 ProteinP29353 (Uniprot-TrEMBL)
SHC1:Phosphorylated ERBB2 heterodimersComplexR-HSA-1248746 (Reactome)
SHC1ProteinP29353 (Uniprot-TrEMBL)
SOS1 ProteinQ07889 (Uniprot-TrEMBL)
STUB1ProteinQ9UNE7 (Uniprot-TrEMBL)
UBA52(1-76) ProteinP62987 (Uniprot-TrEMBL)
UBB(1-76) ProteinP0CG47 (Uniprot-TrEMBL)
UBB(153-228) ProteinP0CG47 (Uniprot-TrEMBL)
UBB(77-152) ProteinP0CG47 (Uniprot-TrEMBL)
UBC(1-76) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(153-228) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(229-304) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(305-380) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(381-456) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(457-532) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(533-608) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(609-684) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(77-152) ProteinP0CG48 (Uniprot-TrEMBL)
USP8ProteinP40818 (Uniprot-TrEMBL)
Ub-ERBB2:ERBB2IP:HSP90:CDC37ComplexR-HSA-1918081 (Reactome)
Ub-ERBB2:ERBB2IP:Ub-HSP90:CDC37ComplexR-HSA-1918083 (Reactome)
Ub-ERBB3ComplexR-HSA-1358735 (Reactome)
Ub-RNF41:p-USP8ComplexR-HSA-1358740 (Reactome)
Ub-RNF41ComplexR-HSA-1358737 (Reactome)
UbComplexR-HSA-113595 (Reactome)
p-10Y-ERBB3-1 ProteinP21860-1 (Uniprot-TrEMBL)
p-4Y-PLCG1ProteinP19174 (Uniprot-TrEMBL)
p-6Y-EGFR ProteinP00533 (Uniprot-TrEMBL)
p-6Y-ERBB2 ProteinP04626 (Uniprot-TrEMBL)
p-7Y-ERBB2 ProteinP04626 (Uniprot-TrEMBL)
p-ERBB2 heterodimers:MATKComplexR-HSA-1963590 (Reactome)
p-ERBB2 heterodimersComplexR-HSA-1963588 (Reactome)
p-T305,S472-AKT3 ProteinQ9Y243 (Uniprot-TrEMBL)
p-T308,S473-AKT1 ProteinP31749 (Uniprot-TrEMBL)
p-T309,S474-AKT2 ProteinP31751 (Uniprot-TrEMBL)
p-T945-USP8 ProteinP40818 (Uniprot-TrEMBL)
p-T945-USP8ProteinP40818 (Uniprot-TrEMBL)
p-Y,Y877-ERBB2 ProteinP04626 (Uniprot-TrEMBL)
p-Y-ERBB2 ProteinP04626 (Uniprot-TrEMBL)
p-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform ProteinQ15303-2 (Uniprot-TrEMBL)
p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform ProteinQ15303-1 (Uniprot-TrEMBL)
p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersComplexR-HSA-1250194 (Reactome)
p-Y349,Y350-SHC1 ProteinP29353 (Uniprot-TrEMBL)
p-Y419/420/426-N-myristoyl-SRC/FYN/YES1ComplexR-HSA-1810413 (Reactome)
p-Y877-ERBB2 heterodimersComplexR-HSA-1963584 (Reactome)
p-Y877-ERBB2 ProteinP04626 (Uniprot-TrEMBL)
p21 RAS:GDPComplexR-HSA-109796 (Reactome)
p21 RAS:GTPComplexR-HSA-109783 (Reactome)

Annotated Interactions

View all...
SourceTargetTypeDatabase referenceComment
ADPArrowR-HSA-1250195 (Reactome)
ADPArrowR-HSA-1250462 (Reactome)
ADPArrowR-HSA-1251922 (Reactome)
ADPArrowR-HSA-1306957 (Reactome)
ADPArrowR-HSA-1306979 (Reactome)
ADPArrowR-HSA-1358791 (Reactome)
ADPArrowR-HSA-1963581 (Reactome)
ADPArrowR-HSA-1963582 (Reactome)
ADPArrowR-HSA-1963586 (Reactome)
ATPR-HSA-1250195 (Reactome)
ATPR-HSA-1250462 (Reactome)
ATPR-HSA-1251922 (Reactome)
ATPR-HSA-1306957 (Reactome)
ATPR-HSA-1306979 (Reactome)
ATPR-HSA-1358791 (Reactome)
ATPR-HSA-1963581 (Reactome)
ATPR-HSA-1963582 (Reactome)
ATPR-HSA-1963586 (Reactome)
Active AKTmim-catalysisR-HSA-1358791 (Reactome)
CDC37ArrowR-HSA-1963589 (Reactome)
CUL5mim-catalysisR-HSA-1918095 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PI3KArrowR-HSA-1306966 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PI3Kmim-catalysisR-HSA-1306957 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PIK3R1ArrowR-HSA-1306965 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1:PIK3R1R-HSA-1306966 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1ArrowR-HSA-1306963 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:GAB1R-HSA-1306965 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:SOS1ArrowR-HSA-1250488 (Reactome)
EGF:p-EGFR:p-ERBB2:GRB2:SOS1mim-catalysisR-HSA-1250498 (Reactome)
EGF:p-EGFR:p-ERBB2:PLCG1ArrowR-HSA-1251944 (Reactome)
EGF:p-EGFR:p-ERBB2:PLCG1R-HSA-1251922 (Reactome)
EGF:p-EGFR:p-ERBB2:PLCG1mim-catalysisR-HSA-1251922 (Reactome)
ERBB2 heterodimersArrowR-HSA-1963589 (Reactome)
ERBB2 heterodimersR-HSA-1963582 (Reactome)
ERBB2 heterodimersR-HSA-1963586 (Reactome)
ERBB2 heterodimersmim-catalysisR-HSA-1963582 (Reactome)
ERBB2:ERBB2IP:HSP90:CDC37R-HSA-1918092 (Reactome)
ERBB2:ERBB2IP:HSP90:CDC37R-HSA-1918095 (Reactome)
ERBB2:ERBB2IP:HSP90:CDC37R-HSA-1963589 (Reactome)
ERBB2IPArrowR-HSA-1963589 (Reactome)
ERBB3-1R-HSA-1247497 (Reactome)
ERBB3-1R-HSA-1358801 (Reactome)
ERBB3:RNF41ArrowR-HSA-1358801 (Reactome)
ERBB3:RNF41R-HSA-1358790 (Reactome)
ERBB3:RNF41mim-catalysisR-HSA-1358790 (Reactome)
GDPArrowR-HSA-1250463 (Reactome)
GDPArrowR-HSA-1250498 (Reactome)
GDPArrowR-HSA-1306972 (Reactome)
GRB2-1:SOS1R-HSA-1250486 (Reactome)
GRB2-1:SOS1R-HSA-1250488 (Reactome)
GRB2-1:SOS1R-HSA-1306969 (Reactome)
GRB2:GAB1R-HSA-1306963 (Reactome)
GRB2:SOS1:p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersArrowR-HSA-1250486 (Reactome)
GRB2:SOS1:p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersmim-catalysisR-HSA-1250463 (Reactome)
GRB7R-HSA-1306953 (Reactome)
GTPR-HSA-1250463 (Reactome)
GTPR-HSA-1250498 (Reactome)
GTPR-HSA-1306972 (Reactome)
HSP90ArrowR-HSA-1963589 (Reactome)
Ligand-Activated EGFR/ERBB3/ERBB4R-HSA-1963589 (Reactome)
MATKR-HSA-1963563 (Reactome)
NRG1/2:ERBB3ArrowR-HSA-1247497 (Reactome)
NRG1/2:Ub-p-10Y-ERBB3:p-ERBB2ArrowR-HSA-1358792 (Reactome)
NRG1/2:p-10Y-ERBB3:p-ERBB2:GRB7ArrowR-HSA-1306953 (Reactome)
NRG1/2:p-10Y-ERBB3:p-ERBB2:RNF41ArrowR-HSA-1358798 (Reactome)
NRG1/2:p-10Y-ERBB3:p-ERBB2:RNF41R-HSA-1358792 (Reactome)
NRG1/2:p-10Y-ERBB3:p-ERBB2:RNF41mim-catalysisR-HSA-1358792 (Reactome)
NRG1/2:p-ERBB3:p-ERBB2:PI3KArrowR-HSA-1250466 (Reactome)
NRG1/2:p-ERBB3:p-ERBB2:PI3Kmim-catalysisR-HSA-1250462 (Reactome)
NRG1/2:p-ERBB3:p-ERBB2:PIK3R1ArrowR-HSA-1250189 (Reactome)
NRG1/2:p-ERBB3:p-ERBB2:PIK3R1R-HSA-1250466 (Reactome)
NRG1/2R-HSA-1247497 (Reactome)
NRGs/EGFLs:p-ERBB4:p-ERBB2:GRB2:SOS1ArrowR-HSA-1306969 (Reactome)
NRGs/EGFLs:p-ERBB4:p-ERBB2:GRB2:SOS1mim-catalysisR-HSA-1306972 (Reactome)
NRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PI3KArrowR-HSA-1306980 (Reactome)
NRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PI3Kmim-catalysisR-HSA-1306979 (Reactome)
NRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PIK3R1ArrowR-HSA-1250346 (Reactome)
NRGs/EGFLs:p-ERBB4cyt1:p-ERBB2:PIK3R1R-HSA-1306980 (Reactome)
PI(3,4,5)P3ArrowR-HSA-1250462 (Reactome)
PI(3,4,5)P3ArrowR-HSA-1306957 (Reactome)
PI(3,4,5)P3ArrowR-HSA-1306979 (Reactome)
PI(4,5)P2R-HSA-1250462 (Reactome)
PI(4,5)P2R-HSA-1306957 (Reactome)
PI(4,5)P2R-HSA-1306979 (Reactome)
PIK3CAR-HSA-1250466 (Reactome)
PIK3CAR-HSA-1306966 (Reactome)
PIK3CAR-HSA-1306980 (Reactome)
PIK3R1R-HSA-1250189 (Reactome)
PIK3R1R-HSA-1250346 (Reactome)
PIK3R1R-HSA-1306965 (Reactome)
PLCG1R-HSA-1251944 (Reactome)
Phosphorylated

ERBB2:EGFR

heterodimers		ArrowR-HSA-1251922 (Reactome)
Phosphorylated

ERBB2:EGFR

heterodimers		R-HSA-1250488 (Reactome)
Phosphorylated

ERBB2:EGFR

heterodimers		R-HSA-1251944 (Reactome)
Phosphorylated

ERBB2:EGFR

heterodimers		R-HSA-1306963 (Reactome)
Phosphorylated

ERBB2:ERBB3

heterodimers		R-HSA-1250189 (Reactome)
Phosphorylated

ERBB2:ERBB3

heterodimers		R-HSA-1306953 (Reactome)
Phosphorylated

ERBB2:ERBB3

heterodimers		R-HSA-1358798 (Reactome)
Phosphorylated

ERBB2:ERBB4

heterodimers		R-HSA-1306969 (Reactome)
Phosphorylated

ERBB2:ERBB4cyt1

heterodimers		R-HSA-1250346 (Reactome)
Phosphorylated

p-6Y-ERBB2

heterodimers		ArrowR-HSA-1963582 (Reactome)
Phosphorylated

p-Y877-ERBB2

heterodimers		ArrowR-HSA-1963581 (Reactome)
R-HSA-1247497 (Reactome) ERBB3 becomes activated by binding either neuregulin 1 (NRG1) or neuregulin 2 (NRG2).
R-HSA-1250189 (Reactome) Membrane associated p85 subunit of PI3K (PIK3R1) binds to phosphorylated tyrosine residues of ERBB3 (Y1054, Y1197, Y1222, Y1224, Y1276 and Y1289) in complex with ERBB2.
R-HSA-1250195 (Reactome) Once bound to ERBB2 heterodimers, SHC1 is phosphorylated on tyrosine residues by the tyrosine kinase activity of either ERBB2 or its heterodimerization partners EGFR and ERBB4.
R-HSA-1250346 (Reactome) p85 subunit of PI3K (PIK3R1) directly binds to any of the two phosphorylated ERBB4 CYT1 isoforms in complex with ERBB2 through interaction with a phosphorylated tyrosine residue in the C-tail of ERBB4 CYT1 (Y1056 in ERBB4 JM-A CYT1; Y1046 in ERBB4 JM-B CYT1).
R-HSA-1250462 (Reactome) Activated PI3K complex directly bound to phosphorylated heterodimer of ERBB2 and ERBB3 phosphorylates PIP2 and converts it into PIP3, leading to activation of AKT signaling.
R-HSA-1250463 (Reactome) SOS1, bound to GRB2 in complex with phosphorylated SHC1 and phosphorylated ERBB2 dimers, catalyzes guanyl-nucleotide exchange on RAS.
R-HSA-1250466 (Reactome) PI3K subunit p85 (PIK3R1) bound to ERBB2:p-ERBB3 recruits PI3K subunit p110 (PIK3CA) to form an active PI3K complex.
R-HSA-1250486 (Reactome) Phosphorylated SHC1 bound to phosphorylated ERBB2 dimers recruits GRB2:SOS1 complex.
R-HSA-1250488 (Reactome) Phosphorylated ERBB2:EGFR heterodimer recruits GRB2:SOS1 complex through phosphorylated tyrosine residues on either ERBB2 or EGFR that serve as direct docking sites for GRB2.
R-HSA-1250498 (Reactome) SOS1 bound to GRB2 in complex with phosphorylated ERBB2:EGFR heterodimer catalyzes guanyl-nucleotide exchange on RAS, leading to activation of the MAP kinase cascade.
R-HSA-1251922 (Reactome) Phospholipase C gamma 1 (PLCG1) is phosphorylated by phosphorylated EGFR:ERBB2 heterodimer.
R-HSA-1251944 (Reactome) Phospholipase C gamma 1 (PLCG1) binds to phosphorylated tyrosine Y1023 of ERBB2 or phosphorylated tyrosines Y992 and Y1173 of EGFR.
R-HSA-1306953 (Reactome) Phosphorylated tyrosine residues Y1199 and Y1262 of ERBB3 in complex with ERBB2 are docking sites for GRB7 binding.
R-HSA-1306957 (Reactome) Active PI3K in complex with p-EGFR:p-ERBB2:GRB2:GAB1 phosphorylates PIP2 into PIP3, leading to activation of AKT signaling.
R-HSA-1306963 (Reactome) GAB1 in complex with GRB2 is recruited to activated ERBB2:EGFR heterodimer through phosphorylated tyrosine residues that serve as docking sites for GRB2.
R-HSA-1306965 (Reactome) Regulatory subunit p85 of PI3K (PIK3R1) binds GAB1 in complex with GRB2 and phosphorylated ERBB2:EGFR heterodimer.
R-HSA-1306966 (Reactome) Catalytic subunit p110 of PI3K (PIK3CA) is recruited by the regulatory p85 subunit of PI3K (PIK3R1) bound to GRB2:GAB1 in complex with phosphorylated heterodimer of ERBB2 and EGFR.
R-HSA-1306969 (Reactome) GRB2:SOS1 complex binds to phosphorylated tyrosine residue Y1139 of ERBB2 in complex with ERBB4.
R-HSA-1306972 (Reactome) SOS1 bound to GRB2 in complex with any of the phosphorylated ERBB2:ERBB4 heterodimers catalyzes guanyl-nucleotide exchange on RAS, leading to the activation of the MAP kinase cascade.
R-HSA-1306979 (Reactome) Active PI3K in complex with phosphorylated ERBB2:ERBB4cyt1 heterodimer phosphorylates PIP2 into PIP3, leading to activation of AKT signaling.
R-HSA-1306980 (Reactome) Catalytic subunit p110 of PI3K (PIK3CA) is recruited by the regulatory p85 subunit of PI3K (PIK3R1) directly bound to phosphorylated ERBB2:ERBB4cyt1 heterodimer, resulting in the assembly of an active PI3K complex.
R-HSA-1358789 (Reactome) RNF41 is able to self-ubiquitinate, which keeps its levels low when ERBB3 is unstimulated.
R-HSA-1358790 (Reactome) RNF41 ubiquitinates unstimulated ERBB3, targeting it for degradation and regulating ERBB3 level in the cell.
R-HSA-1358791 (Reactome) Activated AKT phosphorylates USP8, thereby stabilizing it and allowing it to deubiquitinate NRDP1, which results in increased NRDP1 level and downregulation of ERBB3. This represents a negative feedback loop in ERBB3-mediated signaling.
R-HSA-1358792 (Reactome) RNF41 ubiquitinates activated ERBB3, thereby downregulating ERBB3-mediated signaling. This reaction is part of a negative feedback loop in ERBB2:ERBB3 signaling.
R-HSA-1358795 (Reactome) Phosphorylated USP8 deubiquitinates RNF41 and increases RNF41 level in the cell.
R-HSA-1358797 (Reactome) Ubiquitinated RNF41 binds deubiquitinating enzyme USP8, previously activated by phosphorylation on threonine residue T945.
R-HSA-1358798 (Reactome) In addition to regulating the level of unstimulated ERBB3, ubiquitin ligase RNF41 is able to interact with neuregulin-activated ERBB3.
R-HSA-1358801 (Reactome) RNF41 ubiquitin ligase is able to bind unstimulated ERBB3.
R-HSA-1918092 (Reactome) E3 ubiquitin ligase CHIP (STUB1) mediates ERBB2 ubiquitination by associating with the ERBB2 indirectly, through the chaperone protein HSP90. CHIP (STUB1) ubiquitinates both ERBB2 and HSP90, leading to their proteasome-dependent degradation. Ubiquitination of ERBB2 by CHIP (STUB1) is independent of ERBB2 activation.
R-HSA-1918095 (Reactome) E3 ubiquitin ligase Cullin-5 (CUL5) is recruited to the ERBB2 site at the plasma membrane and ubiquitinates ERBB2 in an HSP90-dependent way, targeting it for degradation. Ubiquitination of ERBB2 by CUL5 appears to be independent of CUL5 adaptor proteins ElonginB and ElonginC.
R-HSA-1963563 (Reactome) MATK (also known as CHK or CSK homologous kinase) binds to ERBB2 through phosphorylated tyrosine residue Y1253 in the C-tail of ERBB2 and, through an unknown mechanism, inhibits ERBB2 downstream signaling.
R-HSA-1963578 (Reactome) SHC1 binds phosphorylated ERBB2:EGFR heterodimers through phosphorylated tyrosine residues on either ERBB2 (Y1196, Y1221, Y1222 and Y1248) or EGFR (Y1148 and Y1173). Heterodimers of ERBB2 and ERBB3 recruit SHC1 through a phosphorylated tyrosine residue Y1328 in the C-tail of ERBB3. Heterodimers of ERBB2 and ERBB4 isoforms recruit SHC1 through phosphorylated tyrosines in the C-tail of etiher ERBB2 (Y1196, Y1221, Y1222 and Y1248) or ERBB4 (Y1188 and Y1242 in ERBB4 JM-A CYT1 isoform; Y1178 and Y1232 in ERBB4 JM-B CYT1 isoform; Y1172 and Y1226 in ERBB4 JM-A CYT2 isoform). Association of SHC1 with ERBB2:EGFR and ERBB2:ERBB3 heterodimers was demonstrated in engineered mouse 32D cells in which human ERBB2, EGFR and ERBB3 were expressed. Therefore, these experiments showed association of human ERBB receptor dimers and mouse Shc1. In the case of ERBB2:ERBB4 heterodimers, direct evidence, involving human proteins only, is available.
R-HSA-1963581 (Reactome) Phosphorylation of ERBB2 on tyrosine residue Y877 by SRC family kinases significantly increases trans-autophosphorylation rate of ERBB2 heterodimers, presumably by enabling the kinase domain of ERBB2 to achieve a conformation that positively affects ERBB2 kinase activity. The downstream signaling of phosphorylated ERBB2 heterodimers that are phosphorylated on Y877 of ERBB2, in addition to the known trans-autophosphorylation sites, has not been studied extensively; it is assumed that the behavior of Y877-phosphorylated ERBB2 heterodimers is qualitatively similar to the behavior of trans-autophosphorylated ERBB2 heterodimers which do not harbor this modification.
R-HSA-1963582 (Reactome) Dimers of ERBB2 and EGF-bound EGFR trans-autophosphorylate on six EGFR tyrosine residues and six ERBB2 tyrosine residues to form phosphorylated heterodimers that activate downstream signaling cascades (Ricci et al. 1995, Pinkas-Kramarski et al. 1996, Walton et al. 1990, Margolis et al. 1989, Hazan et al. 1990, Helin et al. 1991).

In heterodimers of ERBB2 and neuregulin-stimulated ERBB3, ERBB2 phosphorylates ERBB3 on tyrosine residues that serve as docking sites for p85 subunit of PI3K (Y1054, Y1197, Y1222, Y1224, Y1260, Y1276 and Y1289), as well as SHC1 (Y1328) and GRB7 (Y1199 and Y1262). Since ERBB3 lacks catalytic activity, it cannot phosphorylate ERBB2. Hovewer, since ERBB2:ERBB3 heterodimers usually oligomerize on the cell surface, ERBB2 can become trans-autophosphorylated by and adjacent ERBB2 protein. It is not known if ERBB2 in the ERBB2:ERBB3 hetero-oligomer is phosphorylated on all conserved tyrosine residues and if the phosphorylation status of ERBB2 in the ERBB2:ERBB3 hetero-oligoimer significantly affects signaling (Li et al. 2007, Pinkas-Kramarski et al. 1996, Prigent et al. 1994, Vijapurkar et al. 2003, Wallasch et al. 1995).

Heterodimers of ERBB2 and ERBB4 trans-autophosphorylate on tyrosine residues that serve as docking sites for PLC-gamma, GRB2 and SHC1, as well as p85 subunit of PI3K (PIK3R1) in the case of ERBB2 heterodimers with ERBB4 CYT1 isoforms (ERBB4cyt1) - ERBB4 JM-A CYT1 and ERBB4 JM-B-CYT1 (Li et al. 2007, Kaushansky et al. 2008, Hazan et al. 1990, Cohen et al. 1996).
R-HSA-1963586 (Reactome) Dissociation of HSP90 from ERBB2 upon formation of ERBB2 heterodimers (with either EGFR, ERBB3 or ERBB4) enables phosphorylation of ERBB2 on the tyrosine residue Y877, mediated by one of SRC family kinases - SRC, FYN or YES1. Although not a mandatory prerequisite of ERBB2 catalytic activity, the phosphorylation at Y877 significantly increases the kinase activity of ERBB2.
R-HSA-1963589 (Reactome) ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member. ERBB2 heterodimerization partners are EGF-stimulated EGFR (Wada et al. 1990, Karunagaran et al. 1996), ERBB3 stimulated by neuregulins NRG1 or NRG2 (Pinkas-Kramarski et al. 1996), and ERBB4 stimulated by neuregulins or EGF-like ligands (Li et al. 2007). In the process of dimerization, ERBB2 dissociates from chaperone proteins HSP90 and CDC37 (Xu et al 2001, Citri et al. 2004). Activated ERBB2 also dissociates from ERBB2IP, the protein reponsible for proper localization of ERBB2 to basolateral membranes of epithelial cells (Borg et al. 2000).
RNF41ArrowR-HSA-1358790 (Reactome)
RNF41ArrowR-HSA-1358792 (Reactome)
RNF41ArrowR-HSA-1358795 (Reactome)
RNF41R-HSA-1358789 (Reactome)
RNF41R-HSA-1358798 (Reactome)
RNF41R-HSA-1358801 (Reactome)
RNF41mim-catalysisR-HSA-1358789 (Reactome)
SHC1:Phosphorylated ERBB2 heterodimersArrowR-HSA-1963578 (Reactome)
SHC1:Phosphorylated ERBB2 heterodimersR-HSA-1250195 (Reactome)
SHC1:Phosphorylated ERBB2 heterodimersmim-catalysisR-HSA-1250195 (Reactome)
SHC1R-HSA-1963578 (Reactome)
STUB1mim-catalysisR-HSA-1918092 (Reactome)
USP8R-HSA-1358791 (Reactome)
Ub-ERBB2:ERBB2IP:HSP90:CDC37ArrowR-HSA-1918095 (Reactome)
Ub-ERBB2:ERBB2IP:Ub-HSP90:CDC37ArrowR-HSA-1918092 (Reactome)
Ub-ERBB3ArrowR-HSA-1358790 (Reactome)
Ub-RNF41:p-USP8ArrowR-HSA-1358797 (Reactome)
Ub-RNF41:p-USP8R-HSA-1358795 (Reactome)
Ub-RNF41:p-USP8mim-catalysisR-HSA-1358795 (Reactome)
Ub-RNF41ArrowR-HSA-1358789 (Reactome)
Ub-RNF41R-HSA-1358797 (Reactome)
UbArrowR-HSA-1358795 (Reactome)
UbR-HSA-1358789 (Reactome)
UbR-HSA-1358790 (Reactome)
UbR-HSA-1358792 (Reactome)
UbR-HSA-1918092 (Reactome)
UbR-HSA-1918095 (Reactome)
p-4Y-PLCG1ArrowR-HSA-1251922 (Reactome)
p-ERBB2 heterodimers:MATKArrowR-HSA-1963563 (Reactome)
p-ERBB2 heterodimersR-HSA-1963563 (Reactome)
p-ERBB2 heterodimersR-HSA-1963578 (Reactome)
p-T945-USP8ArrowR-HSA-1358791 (Reactome)
p-T945-USP8ArrowR-HSA-1358795 (Reactome)
p-T945-USP8R-HSA-1358797 (Reactome)
p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersArrowR-HSA-1250195 (Reactome)
p-Y349,350-SHC1:Phosphorylated ERBB2 heterodimersR-HSA-1250486 (Reactome)
p-Y419/420/426-N-myristoyl-SRC/FYN/YES1mim-catalysisR-HSA-1963586 (Reactome)
p-Y877-ERBB2 heterodimersArrowR-HSA-1963586 (Reactome)
p-Y877-ERBB2 heterodimersR-HSA-1963581 (Reactome)
p-Y877-ERBB2 heterodimersmim-catalysisR-HSA-1963581 (Reactome)
p21 RAS:GDPR-HSA-1250463 (Reactome)
p21 RAS:GDPR-HSA-1250498 (Reactome)
p21 RAS:GDPR-HSA-1306972 (Reactome)
p21 RAS:GTPArrowR-HSA-1250463 (Reactome)
p21 RAS:GTPArrowR-HSA-1250498 (Reactome)
p21 RAS:GTPArrowR-HSA-1306972 (Reactome)
Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP2780"
Personal tools